This article is more than 5 years old. Information may no longer be current.
Artificial hybrid likely required for treating giant cell tumor of bone with zoledronic acid
In a recently published study, researchers determined that to effectively treat giant cell tumors of bone with zoledronic acid, a hybrid including artificial bone would be needed.
The researchers evaluated five patients with giant cell tumor of bone treated with zoledronic acid between 2008 and 2013 at a single institution. The tumors were either grade II or III on the Campanacci scale. Four patients received zoledronic acid with artificial bone, and one patient was administered the treatment without it. Surgically resected specimens were utilized to determine the patients’ histologic response.
The one patient treated without artificial bone exhibited no tumor necrosis and was found to have tumor recurrence locally (in soft tissue) within 18 months of tumor resection. Tumor necrosis was observed in the patients treated with artificial bone. In these patients, the rate of tumor necrosis was 90%, 90%, 50% and 10%, according to the researchers.
The only complication in this study was delayed wound healing, which occurred in two incidences. – by Christian Ingram
Disclosure: The authors have no relevant financial disclosures.